Exploring the potential benefits of Shirodhara as an add-on therapy for alleviating post-COVID anxiety and depression: A case study.
5 affiliations
- 1Department of Panchakarma, Ayurvedic and Unani Tibbia College and Hospital, Govt of NCT of Delhi, India. Electronic address: [email protected].
- 2Department of Panchakarma, All India Institute of Ayurveda, New Delhi, India. Electronic address: [email protected].
- 3Department of Psychiatry, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India. Electronic address: [email protected].
- 4Department of Panchakarma, All India Institute of Ayurveda, New Delhi, India. Electronic address: [email protected].
- 5Department of Panchakarma, Ayurvedic and Unani Tibbia College and Hospital, Govt of NCT of Delhi, India. Electronic address: [email protected].
Abstract
In this case study, we present a 31-year-old female, a homemaker, who developed persistent symptoms of anxiousness, fatigue, weakness, irritation, anger issues, and difficulty concentrating for nearly 12 months following recovery from COVID-19. She was diagnosed by a consulting psychiatrist with post-COVID anxiety with depression, and had been on anxiolytic and antidepressant medications for the past ten months. She underwent Shirodhara (dripping of medicated oil on the forehead) using Balashwagandhadi taila for 14 days as an add-on therapy, while continuing her conventional medications. Assessments at baseline, 8th day, 15th day, and 30th day showed progressive improvements: Hamilton Anxiety Rating Scale (HAM-A) scores reduced from 42 to 10, Hamilton Depression Rating Scale (HDRS) from 23 to 6, Patient Health Questionnaire-9 (PHQ-9) from 24 to 1, and Flanagan Quality of Life Scale (QOLS) improved from 59 to 79 by the 30th day. Serum cortisol was 3.09 μg/dL at baseline, below the normal range, and returned to the normal physiological range (11.76 μg/dL) on the 15th day, reflecting improved stress adaptation. C-Reactive Protein remained stable, while Systemic Immune-Inflammation Index showed a transient, non-pathological rise within normal limits. Also, based on the evaluation and recommendation of the psychiatrist, the dosage of conventional medications was reduced: Propranolol was tapered from 20 mg twice daily to once daily, Clonazepam 0.5 mg at bedtime was shifted to as-needed use, and Omeprazole was discontinued. This case highlights the potential role of Shirodhara as an adjunctive therapy in post-COVID anxiety, along with depression. These findings require validation through larger studies with long-term follow-up.
Related
- Exploring the Renin–Angiotensin System as a Potential Approach for Managing Perimenopausal Depression
- The potential of ruxolitinib as a senomorphic therapy in alleviating neovascular age-related macular degeneration : Ruxolitinib inhibits CNV.
- Feasibility and potential benefits of daily online adaptive radiotherapy for head and neck cancer without margin reduction using an RTT-only workflow
- Potential Benefits and Limitations of Hericium erinaceus Supplementation
- Exploring the association between bullying and depression symptoms among adolescents in Bangladesh: Findings from nationally representative survey
BibTeX
@article{shamkuwar2026exploring,
title = {{Exploring the potential benefits of Shirodhara as an add-on therapy for alleviating post-COVID anxiety and depression: A case study.}},
author = {Manoj Shamkuwar and Anandaraman Pv and Dinesh Kataria and Santosh Bhatted and Bhavna Bhatia},
journal = {Journal of Ayurveda and integrative medicine},
year = {2026},
month = sep,
doi = {10.1016/j.jaim.2026.101407},
url = {https://europepmc.org/article/MED/42858603},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Exploring the potential benefits of Shirodhara as an add-on therapy for alleviating post-COVID anxiety and depression: A case study.
AU - Manoj Shamkuwar
AU - Anandaraman Pv
AU - Dinesh Kataria
AU - Santosh Bhatted
AU - Bhavna Bhatia
PY - 2026
DA - 2026/09/01
JO - Journal of Ayurveda and integrative medicine
DO - 10.1016/j.jaim.2026.101407
UR - https://europepmc.org/article/MED/42858603
AB - In this case study, we present a 31-year-old female, a homemaker, who developed persistent symptoms of anxiousness, fatigue, weakness, irritation, anger issues, and difficulty concentrating for nearly 12 months following recovery from COVID-19. She was diagnosed by a consulting psychiatrist with post-COVID anxiety with depression, and had been on anxiolytic and antidepressant medications for the past ten months. She underwent Shirodhara (dripping of medicated oil on the forehead) using Balashwagandhadi taila for 14 days as an add-on therapy, while continuing her conventional medications. Assessments at baseline, 8th day, 15th day, and 30th day showed progressive improvements: Hamilton Anxiety Rating Scale (HAM-A) scores reduced from 42 to 10, Hamilton Depression Rating Scale (HDRS) from 23 to 6, Patient Health Questionnaire-9 (PHQ-9) from 24 to 1, and Flanagan Quality of Life Scale (QOLS) improved from 59 to 79 by the 30th day. Serum cortisol was 3.09 μg/dL at baseline, below the normal range, and returned to the normal physiological range (11.76 μg/dL) on the 15th day, reflecting improved stress adaptation. C-Reactive Protein remained stable, while Systemic Immune-Inflammation Index showed a transient, non-pathological rise within normal limits. Also, based on the evaluation and recommendation of the psychiatrist, the dosage of conventional medications was reduced: Propranolol was tapered from 20 mg twice daily to once daily, Clonazepam 0.5 mg at bedtime was shifted to as-needed use, and Omeprazole was discontinued. This case highlights the potential role of Shirodhara as an adjunctive therapy in post-COVID anxiety, along with depression. These findings require validation through larger studies with long-term follow-up.
SN - 0975-9476
SN - 0976-2809
ER -